140 related articles for article (PubMed ID: 17524771)
1. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
Frenkel RE; Mani L; Toler AR; Frenkel MP
Am J Ophthalmol; 2007 Jun; 143(6):1034-5. PubMed ID: 17524771
[TBL] [Abstract][Full Text] [Related]
2. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
3. Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma.
Lanzl IM; Maier M; Feucht N; Lohmann CP; Kotliar KE
Am J Ophthalmol; 2008 Jan; 145(1):185; author reply 186. PubMed ID: 18154762
[No Abstract] [Full Text] [Related]
4. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
Hariprasad SM; Shah GK; Blinder KJ
Am J Ophthalmol; 2006 Jan; 141(1):200-1. PubMed ID: 16387003
[TBL] [Abstract][Full Text] [Related]
5. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.
Kim JE; Mantravadi AV; Hur EY; Covert DJ
Am J Ophthalmol; 2008 Dec; 146(6):930-4.e1. PubMed ID: 18775528
[TBL] [Abstract][Full Text] [Related]
6. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
7. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.
Boyer DS; Goldbaum M; Leys AM; Starita C;
Br J Ophthalmol; 2014 Nov; 98(11):1543-6. PubMed ID: 24997182
[TBL] [Abstract][Full Text] [Related]
8. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
Falkenstein IA; Cheng L; Freeman WR
Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
[TBL] [Abstract][Full Text] [Related]
9. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
10. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
[TBL] [Abstract][Full Text] [Related]
11. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs.
Carnota-Méndez P; Méndez-Vázquez C; Otero-Villar J; Saavedra-Pazos JA
Eur J Ophthalmol; 2014; 24(5):771-7. PubMed ID: 24706353
[TBL] [Abstract][Full Text] [Related]
12. The effect of intravitreal triamcinolone on intraocular pressure.
Kramar M; Vu L; Whitson JT; He YG
Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
[TBL] [Abstract][Full Text] [Related]
13. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections.
Skalicky SE; Ho I; Agar A; Bank A
Ophthalmic Surg Lasers Imaging; 2012 Jul; 43(4):328-34. PubMed ID: 22788585
[TBL] [Abstract][Full Text] [Related]
14. Safety of intravitreal injections in patients receiving warfarin anticoagulation.
Dayani PN; Siddiqi OK; Holekamp NM
Am J Ophthalmol; 2007 Sep; 144(3):451-3. PubMed ID: 17765427
[TBL] [Abstract][Full Text] [Related]
15. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of early intraocular pressure changes after a single intravitreal triamcinolone injection.
Im L; Allingham RR; Singh I; Stinnett S; Fekrat S
J Glaucoma; 2008 Mar; 17(2):128-32. PubMed ID: 18344759
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
[TBL] [Abstract][Full Text] [Related]
18. Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma.
Agard E; Elchehab H; Ract-Madoux G; Russo A; Lagenaite C; Dot C
Can J Ophthalmol; 2015 Apr; 50(2):127-31. PubMed ID: 25863852
[TBL] [Abstract][Full Text] [Related]
19. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
[TBL] [Abstract][Full Text] [Related]
20. Short-term intraocular pressure trends after intravitreal triamcinolone injection.
Lee EW; Hariprasad SM; Mieler WF; Newman TL; Apte RS
Am J Ophthalmol; 2007 Feb; 143(2):365-7. PubMed ID: 17258540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
